title: A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.
abstract: As part of a program to develop dopamine D4 antagonists for the treatment of schizophrenia, we discovered a series of 6- and 7-(phenylpiperazinyl)- and -(phenylpiperidinyl)methylbenzoxazinones through mass screening of our compound library. A structure-activity relationship SAR study was carried out involving substituents on the phenyl ring, and several selective D4 antagonists were identified. The 7-substituted benzoxazinones showed more activity in neurochemical and behavioral tests than the 6-substituted series. One of the most potent and selective compounds (26) was found to have potent activity in animal tests predictive of antipsychotic activity in humans after oral administration. This paper describes the SAR of the benzoxazinone series and the preclinical characterization of 26.
authors.affiliation: Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
authors.forename: T R
authors.initials: TR
authors.lastname: Belliotti
authors.forename: D J
authors.initials: DJ
authors.lastname: Wustrow
authors.forename: W A
authors.initials: WA
authors.lastname: Brink
authors.forename: K T
authors.initials: KT
authors.lastname: Zoski
authors.forename: Y H
authors.initials: YH
authors.lastname: Shih
authors.forename: S Z
authors.initials: SZ
authors.lastname: Whetzel
authors.forename: L M
authors.initials: LM
authors.lastname: Georgic
authors.forename: A E
authors.initials: AE
authors.lastname: Corbin
authors.forename: H C
authors.initials: HC
authors.lastname: Akunne
authors.forename: T G
authors.initials: TG
authors.lastname: Heffner
authors.forename: T A
authors.initials: TA
authors.lastname: Pugsley
authors.forename: L D
authors.initials: LD
authors.lastname: Wise
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000737:chemistry / Q000494:pharmacology*; D016466:CHO Cells; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D006224:Cricetinae; D004298:Dopamine / Q000096:biosynthesis / Q000378:metabolism; D018492:Dopamine Antagonists / Q000737:chemistry / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D010078:Oxazines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D050638:Receptors, Dopamine D4
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; C493601:Drd4 protein, rat; D010078:Oxazines; D015102:3,4-Dihydroxyphenylacetic Acid; D050638:Receptors, Dopamine D4; D004298:Dopamine